Chromosome 14q loss is associated with adverse survival and a distinct transcriptional phenotype in IDH-wildtype glioblastoma
Journal of Neuro-Oncology · 2026-11 · 180 (2)
DOI: 10.1007/s11060-026-05855-2 ↗Abstract
Abstract Purpose In IDH-wildtype glioblastoma, prognostic biomarkers beyond MGMT promoter methylation remain limited. Chromosome 14q contains candidate tumor suppressors, yet the significance of arm-level 14q loss in molecularly defined glioblastoma is unclear. Methods Arm-level 14q status was inferred from coordinated 14q expression (Gaussian-mixture model) in bulk RNA sequencing of 215 Japanese IDH-wildtype glioblastomas and validated against methylation-array copy number ( n = 42). Associations with outcome and transcriptional programs were evaluated and assessed in CGGA ( n = 74) and TCGA ( n = 139) using the discovery-cohort threshold. Results RNA-seq-based calls agreed with array copy number in 40/42 cases (κ = 0.90). 14q loss (87/215, 40.5%) was associated with shorter overall ( p = 0.0053) and progression-free survival ( p = 0.0175), remaining prognostic in the prespecified multivariable model (hazard ratio 1.44, 95% confidence interval 1.02–2.01; p = 0.036). 14q loss and MGMT promoter hypomethylation were prognostically complementary (four-group p < 0.0001). Chromosome 14-excluded, purity-adjusted gene set enrichment analysis showed increased E2F-target and G2M-checkpoint and reduced oxidative-phosphorylation and lipid-metabolism programs in 14q-loss tumors. The survival association was reproduced in CGGA ( p = 0.0012) but not in TCGA ( p = 0.55), with significant heterogeneity (interaction p = 0.005). Conclusion RNA-seq-inferable 14q loss identifies a clinically adverse subgroup of Japanese IDH-wildtype glioblastoma, is complementary to MGMT promoter methylation, and is associated with a proliferation-high, oxidative-phosphorylation-low transcriptional state. The absence of this association in TCGA underscores the need for validation in additional population-diverse cohorts before clinical implementation.
EUVIMED